Does Sivextro Treat MRSA?
Yes, Sivextro (tedizolid phosphate) treats MRSA infections. The FDA approved it in 2014 for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of MRSA, Streptococcus pyogenes, Staphylococcus aureus, and Streptococcus agalactiae. Its spectrum includes MRSA, with clinical trials showing non-inferiority to linezolid (another MRSA-active drug) in treating these infections.[1][2]
How Does Sivextro Work Against MRSA?
Sivextro is a prodrug converted to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding the 50S ribosomal subunit. It retains activity against MRSA strains resistant to other classes like beta-lactams or fluoroquinolones, with MIC90 values around 0.5 mcg/mL for MRSA—comparable to or better than linezolid.[3][4]
What MRSA Infections Does It Cover?
Sivextro targets ABSSSI, including cellulitis, wound infections, and major abscesses involving MRSA. It does not have FDA approval for MRSA pneumonia, bacteremia, or osteomyelitis, though off-label use occurs in some resistant cases. Phase 3 trials confirmed 92-98% clinical success rates against MRSA ABSSSI at 80-200 mg daily for 6 days.[2][5]
How Does Sivextro Compare to Other MRSA Treatments?
| Treatment | Class | MRSA Activity | Dosing for ABSSSI | Key Differences from Sivextro |
|-----------|--------|---------------|-------------------|------------------------------|
| Vancomycin | Glycopeptide | Strong | IV 15-20 mg/kg q12h | IV only; nephrotoxic risk; Sivextro is oral/IV, shorter course (6 days vs 7-14). |
| Linezolid | Oxazolidinone | Strong | 600 mg q12h (oral/IV) | Similar efficacy; Sivextro has less myelosuppression, once-daily dosing. |
| Daptomycin | Lipopeptide | Strong | IV 4 mg/kg daily | Better for bacteremia; Sivextro preferred for skin infections due to oral option. |
| Trimethoprim-sulfamethoxazole | Sulfonamide | Moderate | Oral 1-2 DS tabs BID | Cheaper outpatient option; less data in severe MRSA. |
Sivextro edges out linezolid in tolerability for short courses but costs more (~$3,000/course vs $1,000 for generics).[6][7]
Common Side Effects and Patient Concerns with MRSA Treatment
Nausea (8%), headache (6%), and diarrhea (4%) are most reported; myelosuppression is rare at 6-day dosing (vs linezolid's 10-14 days). No QT prolongation or serotonin syndrome risk like linezolid. Patients with MRSA often ask about oral switch—Sivextro allows it after 1-2 IV doses.[2][8]
Who Makes Sivextro and Patent Status?
Merck & Co. markets Sivextro (U.S. rights from Cubist, acquired 2014). Key U.S. patents (e.g., 7,494,976 for tedizolid) expire in 2027-2031, with pediatric exclusivity to 2032. No generics yet; check DrugPatentWatch.com for updates on challenges.[9][10]
Sources
[1]: FDA Label - Sivextro (2019) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205435s007lbl.pdf
[2]: Prokocimer et al., Clin Infect Dis (2013) https://doi.org/10.1093/cid/cit152
[3]: FDA Approval Summary (2014) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sivextro-tedizolid-treat-skin-infections
[4]: Biedenbach et al., Diagn Microbiol Infect Dis (2010) https://doi.org/10.1016/j.diagmicrobio.2010.07.015
[5]: Moran et al., Open Forum Infect Dis (2014) https://doi.org/10.1093/ofid/ofu034
[6]: Clinical efficacy reviews, IDSA Guidelines (2014) https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections/
[7]: Red Book pricing (2023 average)
[8]: Post-marketing data, Merck safety updates
[9]: USPTO Patent Database
[10]: DrugPatentWatch.com https://www.drugpatentwatch.com/p/tradename/SIVEXTRO